Neonatal Fc Receptor Promoter Gene Polymorphism Does Not Predict Pharmacokinetics of IVIg or the Clinical Course of GBS

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2016 Jul 8

PMID 27386503

Citations 9

Authors

Willem-Jan R Fokkink

Annechien E G Haarman

Anne P Tio-Gillen

Wouter van Rijs

Ruth Huizinga

Pieter A van Doorn

Bart C Jacobs

Affiliations

Soon will be listed here.

Abstract

Treatment of Guillain-Barré syndrome with a standard course of high-dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barré syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.

Citing Articles

Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy.

Fisse A, Schafer E, Hieke A, Schroder M, Klimas R, Brunger J Eur J Neurol. 2024; 31(4):e16205.

PMID: 38205888 PMC: 11235998. DOI: 10.1111/ene.16205.

Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.

Fokkink W, van Tilburg S, de Winter B, Sassen S, van Doorn P, Koch B Clin Pharmacokinet. 2022; 61(9):1285-1296.

PMID: 35781631 PMC: 9439991. DOI: 10.1007/s40262-022-01136-z.

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Dalakas M Neurotherapeutics. 2021; 18(4):2397-2418.

PMID: 34766257 PMC: 8585501. DOI: 10.1007/s13311-021-01108-4.

Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.

Al Ojaimi Y, Blin T, Lamamy J, Gracia M, Pitiot A, Denevault-Sabourin C Pharmacol Ther. 2021; 233:108022.

PMID: 34687769 PMC: 8527648. DOI: 10.1016/j.pharmthera.2021.108022.

"Ways in which the neonatal Fc-receptor is involved in autoimmunity".

Lamamy J, Boulard P, Brachet G, Tourlet S, Gouilleux-Gruart V, Ramdani Y J Transl Autoimmun. 2021; 4:100122.

PMID: 34568803 PMC: 8449123. DOI: 10.1016/j.jtauto.2021.100122.

References

Zhou X, Yu L, Zhu L, Hou P, Lv J, Yu F . Association between polymorphisms in the FCGRT gene and lupus nephritis in Chinese patients. Clin Exp Rheumatol. 2009; 27(4):609-14. View

Liu X, Ye L, Bai Y, Mojidi H, Simister N, Zhu X . Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J Immunol. 2008; 181(1):449-63. PMC: 2667120. DOI: 10.4049/jimmunol.181.1.449. View

Dalakas M . High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994; 44(2):223-6. DOI: 10.1212/wnl.44.2.223. View

van der Meche F, Schmitz P . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992; 326(17):1123-9. DOI: 10.1056/NEJM199204233261705. View

Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C . Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013; 171(2):186-94. PMC: 3573289. DOI: 10.1111/cei.12002. View

Sachs U, Socher I, Braeunlich C, Kroll H, Bein G, Santoso S . A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology. 2006; 119(1):83-9. PMC: 1782336. DOI: 10.1111/j.1365-2567.2006.02408.x. View

van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs B, van Doorn P . Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10(8):469-82. DOI: 10.1038/nrneurol.2014.121. View

Cunningham-Rundles C . How I treat common variable immune deficiency. Blood. 2010; 116(1):7-15. PMC: 2904582. DOI: 10.1182/blood-2010-01-254417. View

Rath T, Baker K, Pyzik M, Blumberg R . Regulation of immune responses by the neonatal fc receptor and its therapeutic implications. Front Immunol. 2015; 5:664. PMC: 4283642. DOI: 10.3389/fimmu.2014.00664. View

10.

Vlam L, Cats E, Willemse E, Franssen H, Medic J, Piepers S . Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2013; 85(10):1145-8. DOI: 10.1136/jnnp-2013-306227. View

11.

Qiao S, Lencer W, Blumberg R . How the controller is controlled - neonatal Fc receptor expression and immunoglobulin G homeostasis. Immunology. 2006; 120(2):145-7. PMC: 2265855. DOI: 10.1111/j.1365-2567.2006.02507.x. View

12.

Mikulska J, Pablo L, Canel J, Simister N . Cloning and analysis of the gene encoding the human neonatal Fc receptor. Eur J Immunogenet. 2000; 27(4):231-40. DOI: 10.1046/j.1365-2370.2000.00225.x. View

13.

Roopenian D, Akilesh S . FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-25. DOI: 10.1038/nri2155. View

14.

Ruts L, Drenthen J, Jongen J, Hop W, Visser G, Jacobs B . Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010; 75(16):1439-47. DOI: 10.1212/WNL.0b013e3181f88345. View

15.

Bonilla F . Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008; 28(4):803-19, ix. DOI: 10.1016/j.iac.2008.06.006. View

16.

Kleyweg R, van der Meche F, Schmitz P . Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 1991; 14(11):1103-9. DOI: 10.1002/mus.880141111. View

17.

van Koningsveld R, Schmitz P, Meche F, Visser L, Meulstee J, van Doorn P . Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004; 363(9404):192-6. DOI: 10.1016/s0140-6736(03)15324-x. View

18.

Tesar D, Bjorkman P . An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Curr Opin Struct Biol. 2010; 20(2):226-33. PMC: 2865255. DOI: 10.1016/j.sbi.2010.01.010. View

19.

Hughes R, Perkin G, PIERCE J . Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2(8093):750-3. DOI: 10.1016/s0140-6736(78)92644-2. View

20.

Geleijns K, Jacobs B, van Rijs W, Tio-Gillen A, Laman J, van Doorn P . Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol. 2004; 150(1-2):132-8. DOI: 10.1016/j.jneuroim.2004.01.003. View